- Home
- RA vs VSTM Comparison
RA vs VSTM Comparison
Compare RA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RA | VSTM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.8M | 731.8M |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RA | VSTM |
|---|---|---|
| Price | $11.54 | $7.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 237.7K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $276.56 |
| Revenue Next Year | N/A | $55.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $11.52 | $3.43 |
| 52 Week High | $13.59 | $10.82 |
Technical Indicators
Market Signals| Indicator | RA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 17.84 | 58.37 |
| Support Level | N/A | $7.20 |
| Resistance Level | $12.97 | $8.69 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.00 | 55.59 |
Price Performance
Historical ComparisonAbout RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.